Individuals Stopping Anti-Obesity Injections Put On Pounds at a Quadrupled Rate Than People Using Diet and Exercise

A recent study reveals that patients who stop using popular slimming jabs like semaglutide or tirzepatide can put back on lost weight at a significantly accelerated pace than those who end conventional lifestyle plans.

Published data in a prominent health publication shows that while overweight people can lose about a fifth of their body weight while on the medication, the weight is regained at an average rate of nearly a kilo each month upon discontinuation.

"Individuals purchasing such treatments need to be cognizant of the risk of fast weight regain when the therapy is stopped," cautioned lead investigator Dr. Susan Jebb.

That rate of recovery implies a reversion to pre-treatment weight in about 18 months.

Weighing Therapies

The study, which reviewed 37 of trials involving thousands of patients, compared the effects of GLP-1 agonists with other pills.

Scientists note that individuals who lose weight through diet and exercise generally see a slower weight regain—perhaps 0.1 kg a month—post-intervention.

The Reason for the Fast Regain

Nutrition scientists believe the way of the drugs is key to understanding the heightened rebound.

The injections imitate a natural hormone called glucagon-like peptide-1, which moderates hunger.

"Long-term administration of GLP-1 levels several times higher than the body's typical production might result in the system to produce less of its endogenous GLP-1, and could lessen sensitivity to its effects," noted Dr. Adam Collins, a nutrition researcher.

"Withdrawal of this hormone supplement results in hunger is no longer kept in check, making binge eating a significant risk."

A Chronic Disease?

Medical guidelines advise the jabs for people with weight-linked health risks, accompanied by recommended lifestyle changes.

A number of clinicians contend that, due to the significant potential of weight regain, the therapy might need to be long-term.

This view is reinforced by pharmaceutical companies, who note that the findings "emphasize the persistent character of excess weight," similar to managing diseases like diabetes.

Patient Testimonies

Individuals who have discontinued the medication describe a intense return of cravings.

"It was like a trigger that goes on and I was suddenly extremely hungry," recalled a patient.

This difficulty is worsened if patients have not adopted sustainable dietary or behavioural modifications during treatment.

Significant Adoption

Figures indicate that millions of people in the UK have used weight-loss jabs in the last 12 months, with desire remaining high.

• Use is more common among females than males.
• The middle-aged demographic shows the greatest usage rates.
• Many obtain the drugs through private prescriptions rather than public health services.

Ultimately, experts stress that while GLP-1 drugs are effective agents for shedding pounds, they are not a standalone cure and maintained weight loss relies on combined behavioural management.